Pancreatic Cancer Research

ResearcherUniversity of CologneActive in the last 2 years

Philipp Lohneis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4797-0018; OpenAlex author ID A5003729966. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 4 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 13

  1. Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs,… Co-author DOI 10.1158/2326-6066.cir-24-0299↗
  2. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Last author DOI 10.1007/s00428-020-02987-2↗
  3. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. Co-author DOI 10.1016/j.ebiom.2021.103327↗
  4. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Co-author DOI 10.3389/fonc.2021.670396↗
  5. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13112689↗
  6. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Co-author DOI 10.1158/1078-0432.ccr-19-3034↗
  7. The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer. Co-author DOI 10.3390/ijms21062215↗
  8. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-018-0093-y↗
  9. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.016↗
  10. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Last author DOI 10.1016/j.prp.2016.06.001↗
  11. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treat… Last author DOI 10.1016/j.ejca.2015.05.005↗
  12. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Co-author DOI 10.1038/bjc.2014.495↗
  13. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Co-author DOI 10.1093/annonc/mdu084↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jana Käthe Striefler · 9 shared papers, 2014–2021 · strength 0.61
  2. Marianne Sinn · 9 shared papers, 2014–2021 · strength 0.61
  3. Uwe Pelzer · 9 shared papers, 2014–2021 · strength 0.61
  4. Hanno B. Riess · 9 shared papers, 2014–2021 · strength 0.61
  5. Bruno Valentin Sinn · 8 shared papers, 2014–2021 · strength 0.51
  6. Carsten Denkert · 8 shared papers, 2014–2021 · strength 0.51
  7. Helmut Oettle · 8 shared papers, 2014–2021 · strength 0.51
  8. Marcus Bahra · 7 shared papers, 2014–2021 · strength 0.44
  9. Felix Popp · 3 shared papers, 2020–2025 · strength 0.42
  10. Christiane J. Bruns · 3 shared papers, 2020–2025 · strength 0.42
  11. Alexander Quaas · 2 shared papers, 2021–2025 · strength 0.31
  12. Jiahui Li · 2 shared papers, 2020–2021 · strength 0.23
  13. Yue Zhao · 2 shared papers, 2020–2021 · strength 0.23
  14. Steffen Ormanns · 1 shared paper, 2025 · strength 0.19
  15. Hans Schlößer · 1 shared paper, 2025 · strength 0.19
  16. Stephan Krüger · 1 shared paper, 2025 · strength 0.19
  17. Jonas M. Lehmann · 1 shared paper, 2025 · strength 0.19
  18. Jens Werner · 1 shared paper, 2025 · strength 0.19
  19. Stefan Hubert Boeck · 1 shared paper, 2025 · strength 0.19
  20. Frédérik Damm · 2 shared papers, 2020–2021 · strength 0.19
  21. Anja Jühling · 3 shared papers, 2016–2018 · strength 0.18
  22. Alexander Ioannis Damanakis · 1 shared paper, 2021 · strength 0.12
  23. Andrea Cacciato Insilla · 1 shared paper, 2021 · strength 0.12
  24. Martin Wartenberg · 1 shared paper, 2021 · strength 0.12
  25. Steve E. Kalloger · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.